

Nr. crt.	Cod protocol	Numar EudraCT	Medicament de investigatie clinica testat	Medicament de investigatie clinica comparator	Placebo	Aria terapeutică	Sponsor	International / national	Denumirea studiului (s-a pastrat denumirea originala - in limba engleza)	Faza	Nr. estimat de pacienti pentru Romania	Data autorizarii studiului clinic de catre ANMDM	Data opiniei CNBMDM	Data inceperii studiului	Inchidere studiu la nivel global/ Romania	Inchidere temporara
1	CINC424D2301	2016-004432-38	Ruxolitinib	Cea mai buna terapie posibila	Nu	Afectiuni oncologice	Novartis Pharma AG, Elveția	multicentric	A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogeneic stem cell transplantation (REACH 3)	III	6	3/18/2019				
2	CL3-95005-004	2016-002311-18	Trifluridine / Tipiracil	Nu	Nu	Afectiuni oncologice	Institut de Recherches Internationales Servier, Franța	unicentric	An open-label early access phase IIIb study of trifluridine / tipiracil (S 95005/TAS-102) in patients with a pretreated metastatic colorectal cancer	III	35	3/12/2019				
3	MVT-601-3103	2017-004066-10	Relugolix cu doza mica de estradiol si norethindrone acetate	Nu	Nu	Afectiuni ale aparatului reproducator	Myovant Sciences GmbH, Elveția	multicentric	SPIRIT EXTENSION: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered with Low-Dose Estradiol and Norethindrone Acetate in Women with Endometriosis-Associated Pain	III	14	3/18/2019	12/13/2018			
4	MHE104317	2017-000838-39	Nucala (Mepolizumab)	Nu	Nu	Afectiuni ale sistemului imunitar	GlaxoSmithKline Research & Development Ltd., Marea Britanie	unicentric	Expanded access program for mepolizumab in subjects with hypereosinophilic syndrome	III	4	3/5/2019				
5	INCMGA 0012-203	2018-002941-12	INCMGA00012 (PD-1 Inhibitor)	Nu	Nu	Afectiuni oncologice	Incyte Corporation, SUA	multicentric	A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)	II	0	3/12/2019				
6	Debio 1347-201	2018-003584-53	Debio	Nu	Nu	Afectiuni oncologice	Debiopharm International SA, Elveția	multicentric	A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3	II	8	3/12/2019				
7	M16-852	2017-003978-13	Upadacitinib ABT-494	Nu	Da	Afectiuni ale sistemului musculo-scheletic	AbbVie Deutschland GmbH & Co. KG, Germania	multicentric	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis	III	9	3/28/2019				
8	3151-201-008 RESPINS	2018-001605-93	Brazikumab Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Human	Nu	Da	Afectiuni ale sistemului digestiv	Allergan Ltd., UK	unicentric	A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis	II	8	3/28/2019				